Abstract
Anemia is a common complication in dialysis patients and is associated with impaired quality of life and increased mortality. Erythropoietin stimulating agents (ESA) are commonly used to treat anemia. Given the high costs of ESA, several countries across Europe, Middle East and Africa (EMEA) have introduced policies to improve medication usage and anemia treatment. It has been suggested that decision support tools could improve anemia management by unlocking therapy personalization. The aim of the study was to map value-based reimbursement of anemia management across EMEA and analyze economic aspects of decision support tool utilization in dialysis centers within a large dialysis provider network across.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
